Back to today’s briefing

Story perspectives

£50 Million Vaccine Project Aims to Prevent Cancer

1/28/2025

46 10

Summary

Story summary

Oxford University and GSK are joining forces to revolutionize cancer prevention with a pioneering vaccine aimed at pre-cancerous cells. Backed by a £50 million investment, the GSK-Oxford Cancer Immuno-Prevention Programme will harness cutting-edge technologies, including single-cell genomic sequencing and artificial intelligence, to detect early cellular changes that could lead to cancer.

1 of 1

Story summary

Oxford University and GSK are joining forces to revolutionize cancer prevention with a pioneering vaccine aimed at pre-cancerous cells. Backed by a £50 million investment, the GSK-Oxford Cancer Immuno-Prevention Programme will harness cutting-edge technologies, including single-cell genomic sequencing and artificial intelligence, to detect early cellular changes that could lead to cancer.